GlassScriptPhysician profile
Aimon Sangwanpanich
NPI 1578164166
$2,155.71
in general payments reported to CMS, 2019-2025
14 companies · $679 in 2025
The $679 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $34.28 · 2022: $23.43 · 2023: $369 · 2024: $1,050 · 2025: $679.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,032 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,032.01 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $641.55 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Astrazeneca Pharmaceuticals LP | $475.97 | 2023-2025 | Farxiga, Lokelma |
| Akebia Therapeutics INC | $470.82 | 2022-2025 | Vafseo, Auryxia |
| Novo Nordisk INC | $120.85 | 2025 | Ozempic |
| Otsuka America Pharmaceutical, INC. | $85.01 | 2023-2024 | Jynarque |
| Boehringer Ingelheim Pharmaceuticals, INC. | $84.56 | 2023-2024 | Jardiance |
| Mallinckrodt Hospital Products INC. | $65.99 | 2023 | Acthar |
| Vifor Pharma, INC. | $58.29 | 2024 | Veltassa |
| Amgen INC. | $34.28 | 2021 | |
| Aurinia Pharma U.S., INC. | $27.69 | 2023 | Lupkynis |
| Medtronic, INC. | $26.55 | 2024 | |
| Fresenius USA Marketing, INC. | $24.36 | 2024 | Velphoro |
| Scpharmaceuticals INC. | $22.47 | 2023 | |
| Boston Scientific Corporation | $17.32 | 2024 | Spyglass Discover |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aimon Sangwanpanich listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.